

(Alliance News) - Stocks in London traded higher early on Thursday in the final trading day of a holiday-shortened week, despite some hawkish words fr...


(Alliance News) - Hutchmed (China) Ltd on Friday said it initiated the registration stage of the phase 2/3 clinical trial for sovleplenib, its warm an...


(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:


(Alliance News) - Hutchmed (China) Ltd on Wednesday said phase three data for fruquintinib in combination with paclitaxel showed an improvement in ove...


(Alliance News) - Hutchmed (China) Ltd on Friday said Inmagene Biopharmaceuticals Ltd has exercised options to licence two drug candidates as part of ...


(Sharecast News) - Hutchmed China announced on Friday that Inmagene Biopharmaceuticals has exercised options to licence two drug candidates, IMG-007 a...


(Sharecast News) - Hutchmed China announced the approval of its drug 'Elunate', or fruquintinib, by the Pharmacy and Poisons Board of Hong Kong on Tue...